

IN THE CLAIMS

Amend the claims as follows.

1. (Original) A Chinese hamster ovary tissue-derived CHO cell into which a gene encoding an antibody molecule is introduced, which produces an antibody composition comprising an antibody molecule having complex N-glycoside-linked sugar chains bound to the Fc region, wherein among the total complex N-glycoside-linked sugar chains bound to the Fc region in the composition, the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain is 20% or more.

2. (Previously Amended) The CHO cell according to claim 1, wherein the sugar chain to which fucose is not bound is a complex N-glycoside-linked sugar chain in which fucose is not bound to 6-position of N-acetylglucosamine in the reducing end through $\alpha(1\rightarrow6)$ glycosyl bond.

3. (Previously Amended) The CHO cell according to claim 1, wherein the antibody molecule belongs to an IgG class.

4. (Previously Amended) The CHO cell according to claim 1, wherein the activity of an enzyme relating to the synthesis of an intracellular sugar nucleotide, GDP-fucose and/or the activity of an enzyme relating to the modification of a sugar chain in which of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through

$\alpha(1\rightarrow6)$ glycosyl bond in the complex N-glycoside-linked sugar chain is decreased or deleted.

5. (Original) The CHO cell according to claim 4, wherein the enzyme relating to the synthesis of an intracellular sugar nucleotide, GDP-fucose is an enzyme selected from the group consisting of the following (a), (b) and (c):

- (a) GMD (GDP-mannose 4,6-dehydratase);
- (b) Fx (GDP-keto-6-deoxymannose 3,5-epimerase, 4-reductase);
- (c) GFPP (GDP-beta-L-fucose pyrophosphorylase).

6. (Original) The CHO cell according to claim 5, wherein the GMD is a protein encoded by a DNA of the following (a) or (b):

- (a) a DNA comprising the nucleotide sequence represented by SEQ ID NO:65;
- (b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO:65 under stringent conditions and encodes a protein having GMD activity.

7. (Original) The CHO cell according to claim 5, wherein the GMD is a protein selected from the group consisting of the following (a), (b) and (c):

- (a) a protein comprising the amino acid sequence represented by SEQ ID NO:71;

(b) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:71 and has GMD activity;

(c) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO:71 and has GMD activity.

8. (Original) The CHO cell according to claim 5, wherein the Fx is a protein encoded by a DNA of the following (a) or (b):

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO:48;

(b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO:48 under stringent conditions and encodes a protein having Fx activity.

9. (Original) The CHO cell according to claim 5, wherein the Fx is a protein selected from the group consisting of the following (a), (b) and (c):

(a) a protein comprising the amino acid sequence represented by SEQ ID NO:72;

(b) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:72 and has Fx activity;

(c) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO:72 and has Fx activity.

10. (Original) The CHO cell according to claim 5, wherein the GFPP is a protein encoded by a DNA of the following (a) or (b):

- (a) a DNA comprising the nucleotide sequence represented by SEQ ID NO:51;
- (b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO:51 under stringent conditions and encodes a protein having GFPP activity.

11. (Original) The CHO cell according to claim 5, wherein the GFPP is a protein selected from the group consisting of the following (a), (b) and (c):

- (a) a protein comprising the amino acid sequence represented by SEQ ID NO:73;
- (b) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:73 and has GFPP activity;
- (c) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO:73 and has GFPP activity.

12. (Previously Amended) The CHO cell according to claim 4, wherein the enzyme relating to the modification of a sugar chain in which fucose is bound to 6-position of the N-acetylglucosamine in the reducing end through $\alpha(1\rightarrow6)$ glycosyl bond in the complex N-glycoside-linked sugar chain is α -1,6-fucosyltransferase.

13. (Original) The CHO cell according to claim 12, wherein the α -1,6-fucosyltransferase is a protein encoded by a DNA of the following (a) or (b):

- (a) a DNA comprising the nucleotide sequence represented by SEQ ID NO:1;
- (b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO:1 under stringent conditions and encodes a protein having α -1,6-fucosyltransferase activity.

14. (Original) The CHO cell according to claim 12, wherein the α -1,6-fucosyltransferase is a protein selected from the group consisting of the following (a), (b) and (c):

- (a) a protein comprising the amino acid sequence represented by SEQ ID NO:23;
- (b) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:23 and has α -1,6-fucosyltransferase activity;
- (c) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO:23 and has α -1,6-fucosyltransferase activity.

15. (Previously Amended) The CHO cell according to claim 4, wherein the enzyme activity is decreased or deleted by a technique selected from the group consisting of the following (a), (b), (c), (d) and (e):

- (a) a gene disruption technique targeting a gene encoding the enzyme;
- (b) a technique for introducing a dominant negative mutant of a gene encoding the enzyme;
- (c) a technique for introducing mutation into the enzyme;
- (d) a technique for inhibiting transcription and/or translation of a gene encoding the enzyme;
- (e) a technique for selecting a cell line resistant to a lectin which recognizes a sugar chain in which fucose is bound to 6-position of N-acetylglucosamine in the reducing end through $\alpha(1\rightarrow6)$ glycosyl bond in the complex N-glycoside-linked sugar chain.

16. (Previously Amended) The CHO cell according to claim 4, which is resistant to at least a lectin which recognizes a sugar chain in which fucose is bound to 6-position of N-acetylglucosamine in the reducing end through $\alpha(1\rightarrow6)$ glycosyl bond in the complex N-glycoside-linked sugar chain.

17. (Previously Amended) The CHO cell according to claim 4, which produces an antibody composition having higher antibody-dependent cell-mediated cytotoxic activity than an antibody composition produced by its parent CHO cell.

18. (Original) The CHO cell according to claim 17, which produces an antibody composition having higher antibody-dependent cell-mediated cytotoxic activity than an antibody composition in which among the total complex N-glycoside-linked sugar chains bound to the Fc region contained in the antibody composition, the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain is less than 20%.

19. (Previously Amended) The CHO cell according to claim 18, wherein the sugar chain to which fucose is not bound is a complex N-glycoside-linked sugar chain in which fucose is not bound to 6-position of N-acetylglucosamine in the reducing end through $\alpha(1\rightarrow6)$ glycosyl bond.

20. (Previously Amended) A method for producing an antibody composition, which comprises culturing the CHO cell according to claim 1 in a medium to produce and accumulate an antibody composition in the culture; and recovering the antibody composition from the culture.

21. (Original) An antibody composition which is produced using the method according to claim 20.

22. (Original) An antibody composition which comprises an antibody molecule having complex N-glycoside-linked sugar chains bound to the Fc region which is

produced by a CHO cell, wherein among the total complex N-glycoside-linked sugar chains bound to the Fc region in the composition, the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain is 20% or more.

23. (Previously Amended) A cell in which the activity of an enzyme relating to the synthesis of an intracellular sugar nucleotide, GDP-fucose and/or the activity of an enzyme relating to the modification of a sugar chain wherein fucose is bound to 6-position of N-acetylglucosamine in the reducing end through $\alpha(1\rightarrow6)$ glycosyl bond in the complex N-glycoside-linked sugar chain is decreased or deleted by a genetic engineering technique.

24. (Original) The cell according to claim 23, wherein the enzyme relating to the synthesis of an intracellular sugar nucleotide, GDP-fucose is an enzyme selected from the group consisting of the following (a), (b) and (c):

- (a) GMD (GDP-mannose 4,6-dehydratase);
- (b) Fx (GDP-keto-6-deoxymannose 3,5-epimerase, 4-reductase);
- (c) GFPP (GDP-beta-L-fucose pyrophosphorylase).

25. (Original) The cell according to claim 24, wherein the GMD is a protein encoded by a DNA of the following (a) or (b):

- (a) a DNA comprising the nucleotide sequence represented by SEQ ID NO:65;

(b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO:65 under stringent conditions and encodes a protein having GMD activity.

26. (Original) The cell according to claim 24, wherein the GMD is a protein selected from the group consisting of the following (a), (b) and (c):

(a) a protein comprising the amino acid sequence represented by SEQ ID NO:71;

(b) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:71 and has GMD activity;

(c) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO:71 and has GMD activity.

27. (Original) The cell according to claim 24, wherein the Fx is a protein encoded by a DNA of the following (a) or (b):

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO:48;

(b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO:48 under stringent conditions and encodes a protein having Fx activity.

28. (Original) The cell according to claim 24, wherein the Fx is a protein selected from the group consisting of the following (a), (b) and (c):

(a) a protein comprising the amino acid sequence represented by SEQ ID NO:72;

(b) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:72 and has Fx activity;

(c) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO:72 and has Fx activity.

29. (Original) The cell according to claim 24, wherein the GFPP is a protein encoded by a DNA of the following (a) or (b):

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO:51;

(b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO:51 under stringent conditions and encodes a protein having GFPP activity.

30. (Original) The cell according to claim 24, wherein the GFPP is a protein selected from the group consisting of the following (a), (b) and (c):

(a) a protein comprising the amino acid sequence represented by SEQ ID NO:73;

(b) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:73 and has GFPP activity;

(c) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO:73 and has GFPP activity.

31. (Previously Amended) The cell according to claim 23, wherein the enzyme relating to the modification of a sugar chain in which fucose is bound to 6-position of N-acetylglucosamine in the reducing end through $\alpha(1\rightarrow6)$ glycosyl bond in the N-glycoside-linked sugar chain is α -1,6-fucosyltransferase.

32. (Original) The cell according to claim 31, wherein the α -1,6-fucosyltransferase is a protein encoded by a DNA selected from the group consisting of the following (a), (b), (c) and (d):

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO:1;
(b) a DNA comprising the nucleotide sequence represented by SEQ ID NO:2;
(c) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO:1 under stringent conditions and encodes a protein having α -1,6-fucosyltransferase activity,;

(d) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO:2 under stringent conditions and encodes a protein having α -1,6-fucosyltransferase activity.

33. (Original) The cell according to claim 31, wherein the α -1,6-fucosyltransferase is a protein selected from the group consisting of the following (a), (b), (c), (d), (e) and (f):

(a) a protein comprising the amino acid sequence represented by SEQ ID NO:23;

(b) a protein comprising the amino acid sequence represented by SEQ ID NO:24;

(c) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:23 and has α -1,6-fucosyltransferase activity;

(d) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:24 and has α -1,6-fucosyltransferase activity;

(e) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO:23 and has α -1,6-fucosyltransferase activity;

(f) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO:24 and has α -1,6-fucosyltransferase activity

34. (Previously Amended) The cell according to claim 23, wherein the genetic engineering technique is a technique selected from the group consisting of the following (a), (b), (c) and (d):

- (a) a gene disruption technique targeting a gene encoding the enzyme;
- (b) a technique for introducing a dominant negative mutant of a gene encoding the enzyme;
- (c) a technique for introducing mutation into the enzyme;
- (d) a technique for inhibiting transcription and/or translation of a gene encoding the enzyme.

35. (Previously Amended) The cell according to claim 23, which is resistant to at least a lectin which recognizes a sugar chain in which fucose is bound to 6-position of N-acetylglucosamine in the reducing end through $\alpha(1\rightarrow6)$ glycosyl bond in the N-glycoside-linked sugar chain.

36. (Previously Amended) The cell according to claim 23, which is a cell selected from the group consisting of the following (a) to (i):

- (a) a CHO cell derived from a Chinese hamster ovary tissue;
- (b) a rat myeloma cell line, YB2/3HL.P2.G11.16Ag.20 cell;
- (c) a mouse myeloma cell line, NSO cell;
- (d) a mouse myeloma cell line, SP2/0-Ag14 cell;
- (e) a BHK cell derived from a syrian hamster kidney tissue;
- (f) an antibody-producing hybridoma cell;

- (g) a human leukemia cell line Namalwa cell;
- (h) an embryonic stem cell;
- (i) a fertilized egg cell.

37. (Previously Amended) The cell according to claim 23 into which a gene encoding an antibody molecule is introduced.

38. (Original) The cell according to claim 37, wherein the antibody molecule belongs to an IgG class.

39. (Previously Amended) A method for producing an antibody composition, which comprises culturing the cell according to claim 37 in a medium to produce and accumulate the antibody composition in the culture; and recovering the antibody composition from the culture.

40. (Original) The method according to claim 39, which produces an antibody composition having higher antibody-dependent cell-mediated cytotoxic activity than an antibody composition obtained from its parent cell line.

41. (Previously Amended) An antibody composition which is produced using the method according to claim 39.

42. (Previously Amended) A transgenic non-human animal or plant or the progenies thereof, comprising a genome which is modified such that the activity of an enzyme relating to the synthesis of an intracellular sugar nucleotide, GDP-fucose and/or the activity of an enzyme relating to the modification of a sugar chain in which fucose is bound to 6-position of N-acetylglucosamine in the reducing end through $\alpha(1\rightarrow6)$ glycosyl bond in the N-glycoside-linked sugar chain is decreased.

43. (Previously Amended) The transgenic non-human animal or plant or the progenies thereof according to claim 42, wherein a gene encoding the enzyme relating to the synthesis of an intracellular sugar nucleotide, GDP-fucose or a gene encoding the enzyme relating to the modification of a sugar chain in which fucose is bound to 6-position of N-acetylglucosamine in the reducing end through $\alpha(1\rightarrow6)$ glycosyl bond in the N-glycoside-linked sugar chain is knocked out.

44. (Previously Amended) The transgenic non-human animal or plant or the progenies thereof according to claim 42, wherein the enzyme relating to the synthesis of an intracellular sugar nucleotide, GDP-fucose is an enzyme selected from the group consisting of the following (a), (b) and (c):

- (a) GMD (GDP-mannose 4,6-dehydratase);
- (b) Fx (GDP-keto-6-deoxymannose 3,5-epimerase, 4-reductase);
- (c) GFPP (GDP-beta-L-fucose pyrophosphorylase).

45. (Original) The transgenic non-human animal or plant or the progenies thereof according to claim 44, wherein the GMD is a protein encoded by a DNA of the following (a) or (b):

- (a) a DNA comprising the nucleotide sequence represented by SEQ ID NO:65;
- (b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO:65 under stringent conditions and encodes a protein having GMD activity.

46. (Original) The transgenic non-human animal or plant or the progenies thereof according to claim 44, wherein the Fx is a protein encoded by a DNA of the following (a) or (b):

- (a) a DNA comprising the nucleotide sequence represented by SEQ ID NO:48;
- (b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO:48 under stringent conditions and encodes a protein having Fx activity.

47. (Original) The transgenic non-human animal or plant or the progenies thereof according to claim 44, wherein the GFPP is a protein encoded by a DNA of the following (a) or (b):

- (a) a DNA comprising the nucleotide sequence represented by SEQ ID NO:51;
- (b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO:51 under stringent conditions and encodes a protein having GFPP activity.

48. (Previously Amended) The transgenic non-human animal or plant or the progenies thereof according to claim 42, wherein the enzyme relating to the modification of a sugar chain in which fucose is bound to 6-position of N-acetylglucosamine in the reducing end through $\alpha(1\rightarrow6)$ glycosyl bond in the N-glycoside-linked sugar chain is α -1,6-fucosyltransferase.

49. (Original) The transgenic non-human animal or plant or the progenies thereof according to claim 48, wherein the α -1,6-fucosyltransferase is a protein encoded by a DNA selected from the group consisting of the following (a), (b), (c) and (d):

- (a) a DNA comprising the nucleotide sequence represented by SEQ ID NO:1;
- (b) a DNA comprising the nucleotide sequence represented by SEQ ID NO:2;
- (c) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO:1 under stringent conditions and encodes a protein having α -1,6-fucosyltransferase activity;
- (d) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO:2 under stringent conditions and encodes a protein having α -1,6-fucosyltransferase activity.

50. (Previously Amended) The transgenic non-human animal or plant or the progenies thereof according to claim 42, wherein the transgenic non-human animal is an animal selected from the group consisting of cattle, sheep, goat, pig, horse, mouse, rat, fowl, monkey and rabbit.

51. (Previously Amended) A method for producing an antibody composition, which comprises introducing a gene encoding an antibody molecule into the transgenic non-human animal or plant or the progenies thereof according to claim 42; rearing the animal or plant; isolating tissue or body fluid comprising the introduced antibody composition from the reared animal or plant; and recovering the antibody composition from the isolated tissue or body fluid.

52. (Original) The method according to claim 51, wherein the antibody molecule belongs to an IgG class.

53. (Previously Amended) The method according to claim 51, which produces an antibody composition having higher antibody-dependent cell-mediated cytotoxic activity than an antibody composition obtained from a non-human animal or plant or the progenies thereof whose genome is not modified.

54. (Previously Amended) An antibody composition which is produced using the method according to claim 51.

55. (Original) A medicament comprising the antibody composition according to any one of claims 21, 22, 41 and 54 as an active ingredient.

56. (Original) The medicament according to claim 55, wherein the medicament is a diagnostic drug, a preventive drug or a therapeutic drug for diseases accompanied by tumors, diseases accompanied by allergies, diseases accompanied by inflammations, autoimmune diseases, circulatory organ diseases, diseases accompanied by viral infections or diseases accompanied by bacterial infections.

57. (Original) A protein selected from the group consisting of the following (a), (b), (c), (d), (e), (f), (g), (h), (i) and (j):

(a) a protein comprising the amino acid sequence represented by SEQ ID NO:71;

(b) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:71 and has GMD activity;

(c) a protein comprising the amino acid sequence represented by SEQ ID NO:72;

(d) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:72 and has Fx activity;

(e) a protein comprising the amino acid sequence represented by SEQ ID NO:73;

(f) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:73 and has GFPP activity;

(g) a protein comprising the amino acid sequence represented by SEQ ID NO:23;

(h) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:23 and has α -1,6-fucosyltransferase activity;

(i) a protein comprising the amino acid sequence represented by SEQ ID NO:24;

(j) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:24 and the α -1,6-fucosyltransferase activity.

58. (Original) A DNA which encodes the protein according to claim 57.

59. (Original) A DNA selected from the group consisting of the following (a), (b), (c), (d) and (e):

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO:1;

(b) a DNA comprising the nucleotide sequence represented by SEQ ID NO:2;

(c) a DNA comprising the nucleotide sequence represented by SEQ ID NO:65;

(d) a DNA comprising the nucleotide sequence represented by SEQ ID NO:48;

(e) a DNA comprising the nucleotide sequence represented by SEQ ID NO:51.

60. (Original) A genome DNA selected from the group consisting of the following (a), (b) and (c):

(a) a genome DNA comprising the nucleotide sequence represented by SEQ ID NO:3;

(b) a genome DNA comprising the nucleotide sequence represented by SEQ ID NO:67;

(c) a genome DNA comprising the nucleotide sequence represented by SEQ ID NO:70.

61. (Original) A target vector for homologous recombination, comprising a full length of the DNA according to any one of claims 58 to 60, or a part thereof.

62. (new) The CHO cell according to claim 4, wherein the cell produces an antibody composition comprising an antibody molecule having complex *N*-glycoside-linked sugar chains bound to the Fc region, wherein among the total complex *N*-glycoside-linked sugar chains bound to the Fc region in the composition, the ratio of a sugar chain in which fucose is not bound to *N*-acetylglucosamine in the reducing end in the sugar chain is 20% or more.

63. (new) The CHO cell according to claim 4, wherein the sugar chain to which fucose is not bound is a complex *N*-glycoside-linked sugar chain in which fucose is not bound to 6-position of *N*-acetylglucosamine in the reducing end through $\alpha(1\rightarrow6)$ glycosyl bond.

KANDA, et al.

Appl. No. 09/971,773

Monday, December 8, 2003

64. (new) The CHO cell according to claim 4, wherein the antibody molecule belongs to an IgG class.